口服埃达拉 - 介绍一个灵活的治疗方案,用于肌缩侧面硬化症
Gary L Pattee1, Angela Genge2, Philippe Couratier3
1Neurological Sciences Department, University of Nebraska Medical Center/Neurology Associates, Lincoln, Nebraska, USA.
Expert review of neurotherapeutics
|August 30, 2023
概括
口服埃达拉为肌缩侧面硬化症 (ALS) 患者提供了一种新的治疗选择,有可能减缓运动功能的下降. 本综述详细介绍了其药理动力学,安全性和疗效,扩大了治疗的可访问性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病,治疗选择有限.
- 美国食品和药物管理局 (FDA) 在2017年批准了静脉注射 (IV) edaravone,并在2022年批准了口服edaravone用于ALS治疗.
研究的目的:
- 审查口服埃达拉的药理动力学,药理动力学,安全性和疗效.
- 讨论口服edaravone的临床特征和开发计划.
- 总结已完成和正在进行的临床试验的发现.
主要方法:
- 用美国国家医学图书馆的PubMed.gov进行文献评论.
- 分析已公布的关于口服埃达拉临床概况的数据.
- 包括来自口服埃达拉临床试验开发计划的数据.
主要成果:
- 埃达拉在减缓ALS患者运动功能的恶化速度方面表现出有效性.
- 口服配方为患者提供了方便的注射途径.
- 持续的研究和现实世界的证据正在扩大对口服edaravone临床功效的理解.
结论:
- 口服埃达拉代表了ALS药疗中的重大进步.
- 患者现在可以专门使用口服药物治疗ALS.
- 进一步的研究是必不可少的,以充分阐明长期的临床特征和口服埃达拉的好处.
相关概念视频
Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
200
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
200
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Antiepileptic Drugs: Potassium Channel Activators
210
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
210


